Physician profile
Lindsey Fuller
NPI 1942613765
$1,382.10
in general payments reported to CMS, 2019-2025
18 companies · $544 in 2025
The $544 reported for 2025 was more than what 75% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $254 · 2023: $513 · 2024: $70.00 · 2025: $544.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,128.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,127.74 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $389.52 | 2022-2025 | Rybelsus, Ozempic, Wegovy |
| Viiv Healthcare Company | $143.06 | 2024-2025 | Apretude, Rukobia |
| Abbvie INC. | $139.80 | 2023-2025 | |
| Merck Sharp & Dohme LLC | $119.34 | 2025 | Pifeltro, Capvaxive, Delstrigo |
| Lilly USA, LLC | $91.15 | 2022-2025 | Mounjaro, Jardiance |
| Exact Sciences Corporation | $79.74 | 2023-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
| Verity Pharmaceuticals INC. | $67.81 | 2025 | Tlando |
| Idorsia Pharmaceuticals US INC | $65.72 | 2023 | Quviviq |
| Pfizer INC. | $50.54 | 2023-2024 | |
| Gilead Sciences, INC. | $49.59 | 2023-2025 | |
| Biohaven Pharmaceutical Holding Company LTD. | $35.30 | 2022 | |
| Novartis Pharmaceuticals Corporation | $28.22 | 2023 | |
| Astellas Pharma US INC | $27.27 | 2025 | Veozah |
| Abbott Laboratories | $22.05 | 2025 | Freestyle Libre 3 |
| Sanofi Pasteur INC. | $19.30 | 2025 |
Show all 18 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $19.12 | 2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $18.78 | 2022 | |
| Otsuka America Pharmaceutical, INC. | $15.79 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Lindsey Fuller listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.